Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Vividion Therapeutics, Inc.
HC Biopharma Inc.
University of California, Davis
M.D. Anderson Cancer Center
University of California, Irvine
Pfizer
Amgen
Incyte Corporation
University of Colorado, Denver
M.D. Anderson Cancer Center
University of Utah
Dana-Farber Cancer Institute
Fate Therapeutics
Washington University School of Medicine
IDEAYA Biosciences
BioNTech SE
M.D. Anderson Cancer Center
SillaJen, Inc.
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Nurix Therapeutics, Inc.
First Affiliated Hospital of Zhejiang University
University of Chicago
Peking University Cancer Hospital & Institute
Ohio State University Comprehensive Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Txinno Bioscience Inc.
Onward Therapeutics
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Light Chain Bioscience - Novimmune SA
National University Hospital, Singapore